Endpoint
Fasting blood glucose
Glucose in blood.
CAT:outcome/fasting-blood-glucosereported in mg/dL47 findings from 27 compounds
What moved it
How to read these marks47 findings · 27 compounds · 18 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| curcumin | down 5 · no effect 2 | 7 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| berberine | down 4 · no effect 1 | 5 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| magnesium(2+) | down | 5 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| coenzyme Q10 | no effect 2 · down 2 | 4 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| chromium(3+) | no effect | 2 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| melatonin | down | 2 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| resveratrol | no effect 1 · down 1 | 2 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| (R)-carnitine | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| empagliflozin | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| folic acid | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| L-glutamine | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| lipoic acid | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| piperine | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| pravastatin | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| taurine | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| thiamine | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| tirzepatide | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| Zn(2+) | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| α-tocopherol | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| (-)-epigallocatechin 3-gallate | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| astaxanthin | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| crocin-1 | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| lycopene | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| quercetin | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| rebaudioside A | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| sucralose | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| aspartame | up | 1 | Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. |
Reported to move it
29 findings
magnesium(2+) — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Compared with placebo, Mg supplementation reduced fasting plasma glucose in people with diabetes.”
Quoted verbatim from Oral Magnesium Supplementation for Treating Glucose Metabolism Parameters in People with or at Risk of Diabetes: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- people with diabetes
Oral Magnesium Supplementation for Treating Glucose Metabolism Parameters in People with or at Risk of Diabetes: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.2021PMID:34836329Permalink
melatonin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The pooled analysis displayed that melatonin supplementation substantially lowered serum FBG levels in the melatonin group compared with the placebo group (WMD: −11.63 mg/dL, 95% CI: −19.16, −4.10).”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect -11.63 mean difference, 95% CI -19.16 to -4.1
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249Permalink
L-glutamine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Meta-analysis showed that glutamine supplementation significantly decreased significantly serum levels of FPG [SMD: - 0.73, 95% CI - 1.35, - 0.11, I2: 84.1%] and CRP [SMD: - 0.58, 95% CI - 0.1, - 0.17, I2: 0%].”
Quoted verbatim from Effect of glutamine supplementation on cardiometabolic risk factors and inflammatory markers: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- participants in randomized clinical trials of glutamine supplementation
Effect of glutamine supplementation on cardiometabolic risk factors and inflammatory markers: a systematic review and meta-analysis.2021PMID:33865313Permalink
magnesium(2+) — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Overall, Mg supplementation was associated with a significant reduction in FBG levels compared to the control group in T2DM patients (WMD = –0.58, 95% CI: –0.87, –0.28; P < 0.01).”
Quoted verbatim from Effect of Magnesium Supplements on Improving Glucose Control, Blood Pressure and Lipid Profile in Patients With Type 2 Diabetes Mellitus: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- adults with type 2 diabetes mellitus (T2DM); review pooled trials using oral and intravenous magnesium administration
Effect -0.58 mean difference, 95% CI -0.87 to -0.28
Effect of Magnesium Supplements on Improving Glucose Control, Blood Pressure and Lipid Profile in Patients With Type 2 Diabetes Mellitus: A systematic review and meta-analysis.2025PMID:40641714Permalink
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Twelve studies assessed reduction of FBS indicating curcumin supplementation was associated with a significant reduction in FBS, with MD (95% CI) of −2.05 (−3.08, −1.01) mg/dL, I2 = 0%, see Supplementary Appendix O.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 12 RCTs; glycaemic indices were an additional (secondary) outcome of this review, not a liver endpoint
Effect -2.05 mean difference, 95% CI -3.08 to -1.01
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“The overall evidence showed a statistically significant reduction in FBG in the T2D group from curcumin compared to placebo MD = −11.48 mg/dL, 95%CI (−14.26, −8.70), p < 0.01.”
Quoted verbatim from Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial.. - Study
- meta-analysis
- Population
- adults with type 2 diabetes
Effect -11.48 mean difference, 95% CI -14.26 to -8.7
Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial.2024PMID:39683570Permalink
Show the remaining 23
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Compared with placebo, curcumin treatment significantly reduced FPG and HbA1c (key markers of diabetes progression) at 6, 9, and 12 months (Table 4; C).”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- 1500 mg/day curcuminoid extract
- Population
- obese adults with type 2 diabetes mellitus, secondary endpoint, significant at 6, 9, 12 months
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry fundedPermalink
berberine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“BBR supplementation significantly decreased FBG compared to placebo (WMD = −7.74 mg/dl; 95%CI, −10.79 to −4.70; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -7.74 mean difference, 95% CI -10.79 to -4.7
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
folic acid — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Results revealed significant reductions in FBG (weighted mean difference (WMD): -2.17 mg/dL, 95% CI: -3.69, -0.65, p = 0.005), fasting insulin (WMD: -1.63 pmol/L, 95% CI: -2.53, -0.73, p < 0.001), and HOMA-IR (WMD: -0.40, 95% CI: -0.70, -0.09, p = 0.011) following folic acid supplementation.”
Quoted verbatim from Folic Acid Supplementation Improves Glycemic Control for Diabetes Prevention and Management: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Adults in randomized controlled trials of folic acid supplementation (pooled, 24 studies)
Effect -2.17 mean difference, 95% CI -3.69 to -0.65
Folic Acid Supplementation Improves Glycemic Control for Diabetes Prevention and Management: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.2021PMID:34371867Permalink
piperine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Serum levels of FBS significantly declined in case arm in comparison to control arm after the trial timeline (P value = 0.011).”
Quoted verbatim from The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 5 mg piperine capsule daily
- Population
- Adults with ultrasound grade 2-3 NAFLD and raised ALT, Iran; blood drawn after 12 h overnight fast
The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial.2024PMID:38200253Permalink
tirzepatide — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“As shown in Figure S9 and Table S3, all tirzepatide doses resulted in a significant reduction in FPG levels compared to placebo.”
Quoted verbatim from Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. - Study
- meta-analysis
- Dose
- 5, 10 and 15 mg once weekly
- Population
- Adults with or without type 2 diabetes in placebo-controlled trials, 12 to 72 weeks; all three doses
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.2024PMID:38850440Industry fundedPermalink
taurine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155).”
Quoted verbatim from Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Pooled 25 RCTs (1024 participants) of taurine supplementation, 0.5 to 6 g/day, follow-up 5 to 365 days; MetS-related parameters
Effect -5.882 mean difference, 95% CI -10.747 to -1.018
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.2024PMID:38755142Permalink
coenzyme Q10 — decreases
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Findingreplicated ×1“The administration of CoQ10 resulted in a significant decrease in FBG levels (ESWMD = −5.04, 95% CI: −7.67, −2.40; p < 0.001, I 2 = 58.7%, p = 0.04) (Figure.”
Quoted verbatim from Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.. - Study
- meta-analysis
- Dose
- 110 to 376.6 mg/day CoQ10 across the included meta-analyses
- Population
- Adults with type 2 diabetes, obesity, polycystic ovary syndrome, chronic kidney disease, metabolic syndrome and other cardiometabolic conditions, from the randomised controlled trials pooled by eight meta-analyses.
Effect -5.04 mean difference, 95% CI -7.67 to -2.4
Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.2026PMID:41859772Permalink
coenzyme Q10 — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“CoQ10 supplementation was associated with modest but statistically significant reductions in FBG (-7.33 mg/dL; 95% CI: -10.67 to -3.99), HbA1c (-0.12%; 95% CI: -0.28 to 0.03), and fasting insulin (-0.84 μIU/mL; 95% CI: -1.18 to -0.49) compared to placebo.”
Quoted verbatim from The effects of coenzyme Q10 supplementation on glycemic control in diabetic and non-diabetic individuals: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- adults with and without type 2 diabetes mellitus
The effects of coenzyme Q10 supplementation on glycemic control in diabetic and non-diabetic individuals: a systematic review and meta-analysis.2026PMID:41630501Permalink
berberine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“Berberine lowered fasting glucose (-0.52 mmol/L, 95% CI -0.72 to -0.33; 18 studies, n = 1522), HbA1c (-4.48 mmol/mol, 95% CI -6.53 to -2.44, 7 studies, n = 756), fasting insulin (-2.36 mU/L, 95% CI -3.64 to -1.08, 11 studies, n = 966), HOMA-IR (-0.85, 95% CI -1.16 to -0.53,12 studies, n = 1065), and 2-h postprandial glucose (-1.81 mmol/L, 95% CI -2.37 to -1.24, 4 studies, n = 501).”
Quoted verbatim from Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 1,522
- Population
- Adults in 20 randomized trials of berberine versus placebo, pooled across sexes and diabetes status
Effect -0.52 mean difference, 95% CI -0.72 to -0.33
Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.2023PMID:37598753Permalink
(-)-epigallocatechin 3-gallate — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The meta-analysis demonstrated that EGCG supplementation led to statistically significant, but modest, reductions in fasting blood glucose (FBG), HbA1c, and HOMA-IR.”
Quoted verbatim from Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Pooled across 41 randomized controlled trials of EGCG supplementation (meta-analysis of glycemic index and related parameters).
Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40885603Permalink
melatonin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“The pooled findings indicated that melatonin supplementation significantly reduced fasting glucose (SMD=-6.34; 95% CI, -12.28, -0.40; p=0.04; I2: 65.0) and increased the quantitative insulin sensitivity check index (QUICKI) (SMD=0.01; 95% CI, 0.00, 0.02; p=0.01; I2: 0.0).”
Quoted verbatim from The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Adults enrolled in 12 RCTs of melatonin supplementation for glycaemic control
Effect -6.34 standardised mean difference, 95% CI -12.28 to -0.4
The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2018PMID:30396207Permalink
magnesium(2+) — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“Compared with placebo (n=334), Mg treatment (n=336) reduced fasting plasma glucose (studies=9; SMD=-0.40; 95% CI: -0.80 to -0.00; I2=77%) in people with diabetes.”
Quoted verbatim from Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: a systematic review and meta-analysis of double-blind randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with diabetes, oral magnesium supplementation vs placebo
Effect -0.4 standardised mean difference, 95% CI -0.8 to 0
Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: a systematic review and meta-analysis of double-blind randomized controlled trials.2016PMID:27530471Permalink
magnesium(2+) — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“Consistent with other studies, a higher magnesium intake was associated with lower fasting glucose and insulin.”
Quoted verbatim from Higher magnesium intake is associated with lower fasting glucose and insulin, with no evidence of interaction with select genetic loci, in a meta-analysis of 15 CHARGE Consortium Studies.. - Study
- meta-analysis
- Population
- adults of European descent without known diabetes; cross-sectional pooled analysis of 15 CHARGE Consortium cohort studies
Higher magnesium intake is associated with lower fasting glucose and insulin, with no evidence of interaction with select genetic loci, in a meta-analysis of 15 CHARGE Consortium Studies.2013PMID:23343670Permalink
resveratrol — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Resveratrol consumption significantly reduced fasting glucose, insulin, glycated hemoglobin, and insulin resistance (measured by using the homeostatic model assessment) levels in participants with diabetes.”
Quoted verbatim from Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials.. - Study
- meta-analysis
- Population
- participants with diabetes
Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials.2014PMID:24695890Permalink
crocin-1 — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Results of the pooled random-effect size analysis showed just a significant decreasing effect of crocin supplementation on FBG (WMD: -6.52 mg/l, 95 % CI, -11.96, -1.08; p = 0.019) and TC (WMD: -4.64 mg/l, 95 % CI, -8.19, -1.09; p = 0.010).”
Quoted verbatim from The effect of crocin supplementation on lipid concentrations and fasting blood glucose: A systematic review and meta-analysis and meta-regression of randomized controlled trials.. - Study
- meta-analysis
- Population
- Participants in eight clinical trials of crocin supplementation (nine effect sizes), pooled
Effect -6.52 mean difference, 95% CI -11.96 to -1.08
The effect of crocin supplementation on lipid concentrations and fasting blood glucose: A systematic review and meta-analysis and meta-regression of randomized controlled trials.2020PMID:32951748Permalink
magnesium(2+) — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“After a median duration of 12 weeks, the weighted mean post-intervention fasting glucose was significantly lower in the treatment groups compared with the placebo groups [-0.56 mmol/l (95% CI, -1.10 to -0.01); P for heterogeneity = 0.02].”
Quoted verbatim from Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials.. - Study
- meta-analysis
- Duration
- 3 months
- Dose
- 15 mmol/day (360 mg/day) oral magnesium, median
- Population
- Adults with type 2 diabetes in randomized double-blind controlled trials of oral magnesium supplementation
Effect -0.56 mean difference, 95% CI -1.1 to -0.01
Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials.2006PMID:16978367Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“Curcuminoids supplementation significantly decreased fasting blood glucose (p < 0.01), HbA1c (p = 0.031), and insulin resistance index (HOMA-IR) (p < 0.01) in type 2 diabetic patients.”
Quoted verbatim from Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.. - Study
- RCT
- Participants
- 100
- Duration
- 3 months
- Dose
- 300 mg/day
- Population
- overweight/obese adults with type 2 diabetes (BMI ≥ 24; fasting glucose ≥ 7.0 mmol/L or postprandial glucose ≥ 11.1 mmol/L)
Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.2013PMID:22930403Permalink
quercetin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The results showed that quercetin could effectively reduce FBG levels (MD=-2.57, 95% CI=[-4.60, -0.55], P = 0.01), and the difference was statistically significant (Table 2).”
Quoted verbatim from Effects of quercetin on polycystic ovary syndrome in animal models: a systematic review and meta-analysis.. - Study
- animal · not in humans
- Population
- Meta-analysis of three studies in rodent models of polycystic ovary syndrome (DHEA- or letrozole-induced), quercetin versus model controls given no treatment or vehicle
Effect -2.57 mean difference, 95% CI -4.6 to -0.55
Effects of quercetin on polycystic ovary syndrome in animal models: a systematic review and meta-analysis.2024PMID:38637876Permalink
lycopene — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Contrarily, HbA1c and FPG levels decreased significantly with the higher lycopene intake.”
Quoted verbatim from The role of lycopene for the amelioration of glycaemic status and peripheral antioxidant capacity among the Type II diabetes mellitus patients: a case-control study.. - Study
- case-control
- Population
- Patients with type 2 diabetes mellitus within a case-control study; dietary lycopene by food frequency questionnaire; association with intake level
The role of lycopene for the amelioration of glycaemic status and peripheral antioxidant capacity among the Type II diabetes mellitus patients: a case-control study.2021PMID:34180336Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“The results showed that curcumin consumption can significantly reduce AST (-0.35, (-0.57 to -0.14)), total cholesterol (-0.81, (-1.34 to -0.27)), TG (-0.49, (-0.71 to -0.27)), and FBS (-0.28, (-0.46 to -0.09)) in patients with NAFLD.”
Quoted verbatim from The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- adults with NAFLD, meta-analysis of 14 RCTs
The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.2022PMID:35345991Permalink
berberine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“FPG, FPI, HOMA-IR, HbA1, TG, BMI, and WC were significantly lower in patients who received berberine compared to placebo after 12 weeks of treatment ([Formula: see text]< 0.05).”
Quoted verbatim from Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.. - Study
- RCT
- Duration
- 3 months
- Population
- patients with schizophrenia, bipolar disorder, or schizoaffective psychosis with olanzapine-induced mild metabolic disorders, continuing olanzapine treatment (background, both arms)
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.2021PMID:34961418Permalink
aspartame — increases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“At the blood metabolites level, fasting plasma glucose was significantly higher among the aspartame groups (P = 0·003) and this seems to relate to the amount of ingested aspartame (r = 0·585, P = 0·001) (Table 2).”
Quoted verbatim from The effect of aspartame and sucralose intake on body weight measures and blood metabolites: role of their form (solid and/or liquid) of ingestion.. - Study
- animal · not in humans
- Duration
- 7 weeks
- Dose
- 0.05% aspartame w/w in diet and/or drinking water
- Population
- Male Sprague Dawley rats, 7 weeks of age at start; three aspartame arms (0.05% in diet, in drinking water, or both) pooled against an unsweetened-diet, plain-water control, 7 weeks, overnight fasted at termination
The effect of aspartame and sucralose intake on body weight measures and blood metabolites: role of their form (solid and/or liquid) of ingestion.2022PMID:34420538Permalink
berberine — decreases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Findingreplicated ×3“In comparison to the Con group, FBG levels in the BBR group were reduced during the initial period (p <.05) and were continually reduced in the Sta + BBR group (p <.05; Figure 1a).”
Quoted verbatim from Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice.. - Study
- animal · not in humans
- Dose
- 100 mg/kg once daily by gavage for 55 days
- Population
- Type 2 diabetic db/db mice given berberine alone versus water-treated diabetic controls; the berberine-alone reduction is reported for the initial treatment period only
Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice.2020PMID:31833107Permalink
Measured, no effect detected
18 findings
coenzyme Q10 — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“Additionally, the groups did not differ significantly in terms of the fasting blood glucose, insulin, and HbA1c concentrations.”
Quoted verbatim from Effect of Coenzyme Q10 on Insulin Resistance in Korean Patients with Prediabetes: A Pilot Single-Center, Randomized, Double-Blind, Placebo-Controlled Study.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- coenzyme Q10 200 mg/day for 8 weeks
- Population
- adults with impaired glucose tolerance (prediabetes)
Effect of Coenzyme Q10 on Insulin Resistance in Korean Patients with Prediabetes: A Pilot Single-Center, Randomized, Double-Blind, Placebo-Controlled Study.2018PMID:30151373Permalink
resveratrol — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The results indicated that resveratrol did not improve FBG levels versus placebo (WMD: −3.54 mg/dL, 95% CI: −12.45, 5.38; P=0.44;.”
Quoted verbatim from Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Participants
- 1,151
- Dose
- 8.1-3000 mg/day resveratrol across the pooled trials
- Population
- Adults with type 2 diabetes; whole-population pooled estimate across all 19 RCTs, resveratrol vs placebo
Effect -3.54 mean difference, 95% CI -12.45 to 5.38
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.2022PMID:35685602Permalink
curcumin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“In contrast, the fasting blood glucose levels remained the same in both the curcumin ( p = 0.154, 95% CI: −7.547 to 0.976) and placebo group ( p > 0.999, 95% CI: −5.537 to 5.093).”
Quoted verbatim from Twelve-Week Curcumin Supplementation Improves Glucose Homeostasis and Gut Health in Prediabetic Older Adults: A Pilot, Double-Blind, Placebo-Controlled Trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 80 mg curcumin (Longvida lipophilic matrix), one capsule daily
- Population
- adults aged 60 years or older with prediabetes or overweight/obesity; co-primary endpoint
Twelve-Week Curcumin Supplementation Improves Glucose Homeostasis and Gut Health in Prediabetic Older Adults: A Pilot, Double-Blind, Placebo-Controlled Trial.2025PMID:40647269Permalink
thiamine — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pooled results from three trials demonstrated no statistically significant difference in the FBG level between those who received thiamine supplementation versus placebo after less than 3 months of follow-up (MD, −0.20 mmol/L; CI: −0.69 to 0.29).”
Quoted verbatim from Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Adults with type 2 diabetes; three pooled placebo-controlled trials; follow-up under 3 months
Effect -0.2 mean difference, 95% CI -0.69 to 0.29
Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.2022PMID:36008064Permalink
lipoic acid — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
(R)-carnitine — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Similarly, FBS, TG, and HDLc with L-carnitine intervention presented no significant difference between the intervention and control groups.”
Quoted verbatim from L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 0.75 to 3 g/day across included RCTs, 8 to 24 weeks
- Population
- Adults in nine RCTs (diabetes mellitus, non-alcoholic steatohepatitis, knee osteoarthritis, hemodialysis); five RCTs contributed FBS data; whole-population estimate
L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2020PMID:32932644Permalink
Show the remaining 12
Zn(2+) — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Zinc supplementation did not significantly affect FBG (MD = −0.61; 95% CI −1.83 to 0.60; p = 0.32), with considerable heterogeneity (I 2 = 95%).”
Quoted verbatim from Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Adults and children with type 1 or type 2 diabetes, gestational diabetes or prediabetes in 18 pooled RCTs of zinc supplementation against placebo or standard care
Effect -0.61 mean difference, 95% CI -1.83 to 0.6
Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42594341Permalink
empagliflozin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“In comparison with the control group, empagliflozin treatment can attenuate HOMA-IR levels, the statistical difference was significant (MD: −0.45, 95% CI: −0.90 to 0.00, p = 0.05, I2 = 0%), but there were no significant diversity in HbA1c (MD: −0.10, 95% CI: −0.60 to −0.40, p = 0.70, I2 = 42.79%), FBS (MD: −1.21, 95% CI: −4.98 to 2.55, p = 0.53, I2 = 0%), insulin (MD: 3.63, 95% CI: −7.64 to 14.90, p = 0.53, I2 = 90%), and HOMA2-IR (MD: −0.12, 95% CI: −0.45 to 0.20, p = 0.46, I2 = 0%).”
Quoted verbatim from Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Population
- Patients with NAFLD, pooled across randomized trials of empagliflozin 20 to 24 weeks; control arms were mostly placebo with one glimepiride arm
Effect -1.21 mean difference, 95% CI -4.98 to 2.55
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.2022PMID:35282455Permalink
pravastatin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pravastatin use was not significantly associated with change in glucose metabolism measurements such as fasting glucose, fasting insulin, HOMA-IR (homeostasis model of assessment of insulin resistance) and HbA1c (hemoglobin A1c) from baseline to either week 6 or week 12 (table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline at week 6 and week 12
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
α-tocopherol — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Combining mean differences from these studies showed no significant effect of vitamin E on fasting blood glucose in diabetic patients with significant between-study heterogeneity (MD: -3.35 mg/dL, 95% CI: -8.10 to 1.40, P = 0.16, I2: 82.2%, P < 0.001).”
Quoted verbatim from Effect of vitamin E intake on glycemic control and insulin resistance in diabetic patients: an updated systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Adults with type 1 or type 2 diabetes, diabetic nephropathy or neuropathy; pooled randomised trials of vitamin E supplementation against a control group
Effect -3.35 mean difference, 95% CI -8.1 to 1.4
Effect of vitamin E intake on glycemic control and insulin resistance in diabetic patients: an updated systematic review and meta-analysis of randomized controlled trials.2023PMID:36800965Permalink
chromium(3+) — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“In the entire cohort, differences between placebo and Cr groups for A1c (Δ = 0.12 %) and fasting glucose (Δ = 5.4 mg/dl) were not felt to be statistically significant.”
Quoted verbatim from Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus.. - Study
- RCT
- Duration
- 6 months
- Dose
- 1000 ug Cr daily as chromium picolinate (two 500 ug tablets)
- Population
- Adults aged 30-70 with type 2 diabetes, BMI 25-40, whole randomised cohort (not the insulin-sensitivity responder subgroup); 24 weeks of chromium picolinate versus placebo
Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus.2010PMID:20022616Permalink
chromium(3+) — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×1“No changes were observed in FPG, 2-hour plasma glucose levels, fasting or 2-hour post–oral glucose tolerance test insulin levels, or HOMA-IR as compared with placebo after 6 months of chromium use in either the 500-mcg and 1000-mcg arms (Table 2).”
Quoted verbatim from Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.. - Study
- crossover
- Duration
- 6 months
- Dose
- chromium picolinate 500 mcg or 1000 mcg daily
- Population
- Adults with impaired glucose tolerance, impaired fasting glucose or metabolic syndrome, without diabetes; modified cross-over, 6 months of chromium picolinate versus placebo
Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.2011PMID:20634174Industry fundedPermalink
curcumin — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×1“Nanocurcumin supplementation showed no significant effects on fasting blood glucose (SMD: -0.44; 95% CI: -2.16 to 1.28), HbA1c (SMD: 0.19; 95% CI: -1.26 to 1.65), or lipid profile parameters, including total cholesterol, LDL-C, HDL-C and triglycerides (all p > 0.05).”
Quoted verbatim from Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 389
- Population
- adults with type 2 diabetes mellitus (T2DM)
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42171191Permalink
berberine — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Notably, compared with the placebo, BBR did not change fasting blood glucose (FBG), fasting insulin or fasting proinsulin C-peptide levels (Supplementary Table 2).”
Quoted verbatim from Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.. - Study
- crossover
- Participants
- 15
- Dose
- single oral dose of 1 g berberine tablets
- Population
- 15 healthy men with normal glucose tolerance; secondary observation in a single-dose hyperglycaemic clamp trial, fasting glucose measured after an overnight fast before and after dosing
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.2021PMID:34556670Permalink
coenzyme Q10 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“Triglycerides, HDL-cholesterol, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein (CRP) concentrations did not affect following CoQ10 supplementation.”
Quoted verbatim from The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with chronic kidney disease (CKD)
The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.2018PMID:30417782Permalink
sucralose — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Sucralose did not significantly alter alpha diversity (Shannon index: SMD = -0.00; 95% CI -1.16 to 1.15; p = 0.99; I2 = 25.67%), fasting blood glucose (SMD = -0.04; 95% CI = -0.63 to 0.56; p = 0.88; I2 = 69.61%), and HOMA-IR (SMD = -0.13; 95% CI = -0.36 to 0.10; p = 0.212; I2 = 0.00%).”
Quoted verbatim from Effect of Sucralose Consumption on Gut Microbiota: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- healthy adults; pooled from randomized controlled trials of sucralose consumption
Effect -0.04 standardised mean difference, 95% CI -0.63 to 0.56
Effect of Sucralose Consumption on Gut Microbiota: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42794802Permalink
rebaudioside A — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Changes from baseline for rebaudioside A and placebo, respectively, in fasting glucose (7.5+/-3.7mg/dL and 11.2+/-4.5mg/dL), insulin (1.0+/-0.64microU/mL and 3.3+/-1.5microU/mL), and C-peptide (0.13+/-0.09ng/mL and 0.42+/-0.14ng/mL) did not differ significantly (p>0.05 for all).”
Quoted verbatim from Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus.. - Study
- RCT
- Duration
- 4 months
- Dose
- 1000 mg rebaudioside A for 16 weeks
- Population
- men and women aged 33-75 years with type 2 diabetes mellitus
Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus.2008PMID:18555575Permalink
astaxanthin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Current study revealed that astaxanthin consumption was not associated with FBS, HbA1c, TC, LDL-C, TG, BMI, BW, DBP, and SBP.”
Quoted verbatim from The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults; meta-analysis of randomized controlled trials of astaxanthin supplementation (14 studies)
The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials.2020PMID:32755613Permalink
How it is measured
Venous plasma or serum glucose concentration by clinical enzymatic assay in a sample drawn after an overnight fast of stated duration.
Measured, not recorded
- Subject
- fasting blood glucose
- Measurements
- 85 measurements
- Recorded as a finding
- No
Show what was measured
fasting blood glucose
decreases, MD = -0.31 mmol/L [95% CI: -0.59 to -0.03], P = 0.03, p = 0.03, n = 770
Ginseng significantly reduced fasting blood glucose compared to control (MD = -0.31 mmol/L [95% CI: -0.59 to -0.03], P = 0.03).
PMID:25265315 · both readings recorded this
Fasting blood glucose
decreases, p = 0.01
fasting blood glucose (from 10.6+/-0.9 mmol/L to 6.9+/-0.5 mmol/L, P<.01)
PMID:18442638 · one of two readings recorded this
fasting blood glucose
increases
Fasting blood glucose (mM) | 5.4±0.2 | 6.9±0.4† | 5.6±0.2 | 7.4±0.6†
PMID:25313461 · one of two readings recorded this
fasting blood glucose
decreases
Significant reductions in diastolic blood pressure and fasting blood glucose were observed
PMID:25412840 · one of two readings recorded this
fasting blood glucose
decreases
At weeks 12 and 16, EGCG treatment significantly decreased the blood glucose (by 22-24%)
PMID:29278293 · one of two readings recorded this
fasting blood glucose
no effect
However, there were no significant differences in blood glucose levels between HFW and HFWE groups at weeks 20, 24 and 28
PMID:29278293 · one of two readings recorded this
fasting blood glucose
no effect
Additionally, the groups did not differ significantly in terms of the fasting blood glucose, insulin, and HbA1c concentrations.
PMID:30151373 · one of two readings recorded this
fasting blood glucose
increases
PTE300-supplemented mice, which had fasting blood glucose levels significantly higher than control and PTE100-supplemented mice
PMID:30959933 · one of two readings recorded this
fasting blood glucose
decreases
Green tea was then administered from Day 7 on, and was found to significantly ameliorate STZ-induced hyperglycemia but not to cause hypoglycemia in the control group
PMID:31100973 · one of two readings recorded this
Fasting blood glucose
decreases
fasting blood glucose (MD -0.85; 95% CI -1.45 to -0.24)
PMID:31201013 · one of two readings recorded this
fasting blood glucose
decreases
Compared to HFD mice, EGCG treated group significantly restored the blood glucose, total cholesterol (TC), and triglyceride (TG) levels under fasting conditions (Table 1)
PMID:31614951 · one of two readings recorded this
fasting blood glucose
decreases, p = 0.05
In comparison to the Con group, FBG levels in the BBR group were reduced during the initial period (p <.05) and were continually reduced in the Sta + BBR group (p <.05; Figure 1a)
PMID:31833107 · one of two readings recorded this
fasting blood glucose
decreases, p = 0.05
In comparison to the Con group, FBG levels in the BBR group were reduced during the initial period (p <.05) and were continually reduced in the Sta + BBR group (p <.05; Figure 1a)
PMID:31833107 · one of two readings recorded this
fasting blood glucose
unclear
high-dose FBG [effect size (ES) including all datasets: −6.68; 95% CI: −13.62, 0.27; ES when high-risk studies were excluded (n = 2 excluded): −7.15; 95% CI: −14.20, −0.14]
PMID:32722790 · one of two readings recorded this
fasting blood glucose
decreases
high-dose FBG [effect size (ES) including all datasets: −6.68; 95% CI: −13.62, 0.27; ES when high-risk studies were excluded (n = 2 excluded): −7.15; 95% CI: −14.20, −0.14]
PMID:32722790 · one of two readings recorded this
fasting blood glucose
decreases
Long-duration supplementation showed significant benefits for FBP and HbA1c
PMID:32722790 · one of two readings recorded this
fasting blood glucose
decreases
For T2D outcomes, FBG and HOMA-IR showed significant improvements from low-dose zinc supplementation compared with placebo while HbA1c and HOMA-IR improved from high-dose supplementation compared with placebo
PMID:32722790 · one of two readings recorded this
fasting blood glucose
decreases
Among the T2D risk factors, short-duration supplementation showed significant benefits for FBG and HOMA-IR
PMID:32722790 · one of two readings recorded this
Fasting blood glucose
no effect, n = 20
Chang et al., Australia, 2013 | RCT | T2DM | 20 | Healthy Men: (29.5 ± 3.8) T2DM Patients: (68 ± 1.1) | 7.5 or 15 g glutamine or 350 mL of 0.9% saline | 0–30 min | Significant increase GLP-1, GIP, insulin and glucagon levels Insignificant Fasting blood glucose
PMID:32983244 · one of two readings recorded this
fasting blood glucose
decreases, p = 0.05
The data revealed that the level of fasting blood glucose (AC) and hemoglobin A1c (HbA1c) significantly decreased after 6 months LMF-HSFx treatment (, * p < 0.05, compared to placebo)
PMID:33809062 · one of two readings recorded this
Fasting blood glucose
decreases, p = 0.005
significant reductions in FBG (weighted mean difference (WMD): -2.17 mg/dL, 95% CI: -3.69, -0.65, p = 0.005)
PMID:34371867 · one of two readings recorded this
fasting blood glucose
decreases, Summarized findings suggest that curcumin supplementation can significantly reduce blood glucose and triglycerides levels, including markers of liver function like alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in patients with T2D and NAFLD.
Summarized findings suggest that curcumin supplementation can significantly reduce blood glucose and triglycerides levels, including markers of liver function like alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in patients with T2D and NAFLD.
PMID:34847213 · one of two readings recorded this
fasting blood glucose
decreases, p = 0.001
lowering the fasting blood glucose (p < 0.001)
PMID:34959992 · one of two readings recorded this
fasting blood glucose
Not recorded as a finding: node exists (fasting-blood-glucose) but the isoleucine-specific direction is only reachable by inference from 'reversal reached significance', not stated in words within a self-supporting sentence
Fasting glucose was lower in the FFD group compared to chow, and valine reversed this FFD effect non‐significantly whereas this reversal reached significance in the isoleucine group (Table 1).
PMID:35830259 · one of two readings recorded this
Fasting blood glucose
no effect
MD, 1.30 mmol/L; CI: −0.12 to 2.72
PMID:36008064 · one of two readings recorded this
Fasting blood glucose
no effect
MD, −0.20 mmol/L; CI: −0.69 to 0.29
PMID:36008064 · one of two readings recorded this
Fasting blood glucose
no effect
MD, −0.80 mmol/L, CI: −2.36 to 0.76
PMID:36008064 · one of two readings recorded this
Fasting blood glucose
no effect
MD, 0.60 mmmol/l; CI: −0.93 to 2.13
PMID:36008064 · one of two readings recorded this
Fasting blood glucose
no effect
MD, −0.20 mmol/L; CI: −1.60 to 1.20
PMID:36008064 · one of two readings recorded this
Fasting blood glucose
decreases, p = 0.05
significant decrease in FBG, insulin, HbA1c, HOMO-IR, LDL-c, TG, VLDL, CHOL, LDL-c.HDL-c ratio, AIP, IL-6, and MDA and a significant increase in HDL-c, QUICKI index, BDNF, and TAC compared with the initial value (p for all <.05)
PMID:36101997 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.128, n = 51
FBG | 141.79 (64.53) | 113.13 (56.38) | 0.072 | −28.67 (15.20) | 122.85 (59.11) | 137.11 (75.55) | 0.358 | 14.26 (15.23) | 0.128
PMID:36597167 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.07
< 500 | 15 | -7.13 (-14.99, 0.73) | 0.07 | 87.3 | < 0.001
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.16
MD: -3.35 mg/dL, 95% CI: -8.10 to 1.40, P = 0.16
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.32
α-tocopherol | 21 | -3.75 (-11.21, 3.71) | 0.32 | 88.4 | < 0.001
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.45
Mixed-tocopherols | 1 | 9.00 (-14.72, 32.71) | 0.45 | 0.0 | -
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
unclear, p = 0.05
Tocoterienol | 2 | -4.44 (-8.91, 0.03) | 0.05 | 0.0 | 0.62
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.38
MD: -2.32 mg/dL, 95% CI: -7.55 to 2.91, P = 0.38
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
decreases, p = 0.002
< 10 | 15 | -6.04 (-9.88, -2.21) | 0.002 | 19.1 | 0.24
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.16
High | 28 | -4.10 (-9.81, 1.61) | 0.16 | 83.2 | < 0.001
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.994
Low | 6 | 0.04 (-9.71, 9.78) | 0.994 | 79.7 | < 0.001
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.15
Blinded | 25 | -3.96 (-9.39, 1.47) | 0.15 | 86.5 | < 0.001
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.09
Crossover | 3 | -7.07 (-15.46, 1.32) | 0.09 | 30.1 | 0.23
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.41
Non-blinded | 9 | -2.81 (-9.62, 3.99) | 0.41 | 0 | 0.49
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.29
Parallel | 31 | -2.82 (-8.08, 2.44) | 0.29 | 83.4 | < 0.001
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.2
Non-Western countries | 18 | -4.53 (-11.59, 2.53) | 0.20 | 85.1 | < 0.001
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.67
Western countries | 16 | -0.33 (-1.85, 1.19) | 0.67 | 0.0 | 0.52
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.88
T1DM | 6 | 0.87 (-10.53, 12.27) | 0.88 | 0.0 | 0.94
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.09
T2DM | 27 | -4.42 (-9.63, 0.76) | 0.09 | 85 | < 0.001
PMID:36800965 · one of two readings recorded this
Fasting blood glucose
decreases, p = 0.01
Unclear | 10 | -5.24 (-9.59, -0.88) | 0.01 | 3.3 | 0.40
PMID:36800965 · one of two readings recorded this
fasting blood glucose
no effect
Not recorded as a finding: Sentence reports blood sugar level unchanged with cysteine feeding, but does not state a fasting duration or assay method that the fasting-blood-glucose node requires.
Upon cysteine feeding, fat storage and circulating insulin level were significantly reduced while blood sugar level remained stable.
PMID:37055592 · one of two readings recorded this
Fasting blood glucose
increases, p = 0.001
whereas it made a significant increasing effect on FBG levels (for FBG WMD: 4.49 mg/dL; 95%CI: 2.39 to 6.59; P < 0.001)
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.055
≥ 3 | 5 | 7.57 (-0.17, 15.33) | 0.055 | < 0.001 | 94.8% | 0.247
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
increases, p = 0.01
≥ 100 | 9 | 5.90 (1.40, 10.40) | 0.010 | < 0.001 | 90.5% | 0.205
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
increases, p = 0.036
Both | 8 | 2.62 (0.17, 5.07) | 0.036 | < 0.001 | 97.7%
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.607
Female | 2 | 8.27 (-23.21, 39.76) | 0.607 | < 0.001 | 96.6%
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
increases, p = 0.01
Hyperlipidemic | 2 | 4.41 (1.05, 7.76) | 0.010 | < 0.001 | 99.6%
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
increases, p = 0.013
Male | 2 | 4.46 (0.92, 7.99) | 0.013 | 0.120 | 58.7% | 0.671
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.343
Metabolic syndrome | 3 | 2.46 (-2.63, 7.55) | 0.343 | 0.022 | 73.9% | 0.012
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.057
NAFLD | 1 | -5.89 (-11.96, 0.18) | 0.057 | - | -
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.294
Obese (> 30) | 7 | 3.55 (-3.08, 10.18) | 0.294 | < 0.001 | 93.5% | 0.755
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
increases, p = 0.002
Overweight (25–29.9) | 5 | 4.70 (1.79, 7.61) | 0.002 | < 0.001 | 98.6%
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
increases, p = 0.001
≥ 12 | 7 | 6.24 (3.71, 8.77) | < 0.001 | < 0.001 | 98.3% | 0.040
PMID:37794481 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.063
T2DM | 5 | 10.50 (-0.57, 21.58) | 0.063 | < 0.001 | 85.6%
PMID:37794481 · one of two readings recorded this
fasting blood glucose
no effect, p = 0.17
FBG (MD = −0.09; 95% CI: −0.23, 0.04; peffect = 0.17)
PMID:38542695 · one of two readings recorded this
Fasting blood glucose
decreases, p = 0.001
RESV oral consumption (1 g/day) | Randomized, double‐blind, control trial | 1 g per day for 45 days | 66 diabetic patients | Reduced HbA1c serum levels (p <.04), urinary albumin excretion (p <.001), fasting blood glucose (p <.001), and insulin resistance | Sattarinezhad et al.
PMID:38628180 · one of two readings recorded this
Fasting blood glucose
decreases, p = 0.001
The cinnamon supplementation group showed a significant reduction in fasting blood glucose compared to the baseline and the placebo group (p ≤ 0.001)
PMID:38790615 · one of two readings recorded this
Fasting blood glucose
decreases, p = 0.048
except for a significant reduction in fasting blood glucose levels (p = 0.048) and blood pressure (systolic p = 0.002 and diastolic p = 0.006)
PMID:38790615 · one of two readings recorded this
fasting blood glucose
decreases, p = 0.0034
reduction in fasting blood glucose (FBG) (P = .0034)
PMID:38894639 · one of two readings recorded this
fasting blood glucose
no effect
systolic blood pressure, diastolic blood pressure, fasting blood glucose, insulin, triglyceride and high-density lipoprotein compared with control groups
PMID:38923885 · one of two readings recorded this
fasting blood glucose
no effect, p = 0.05
No significant differences were observed between the groups (p > 0.05) in the fasting blood glucose or postprandial blood glucose concentrations after 6 and 12 weeks of intake in the 75 g OGTT compared with the baseline concentration (30-min (PPG0.5h), 60-min (PPG1h), and 90-min (PPG1.5h)) (Table 6).
PMID:39202546 · one of two readings recorded this
Fasting blood glucose
increases, p = 0.01, n = 85
Fasting blood glucose (mmol/L) | 5.8 (1.2) | 6.4 (1.3) |.01
PMID:39403054 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.39, n = 284
FBS | 7 | 284 | (−0.23, 0.38) | 0.2 | 2.90% (0.00% to 0.60%) | 0.04 | 0.125 (−0.16 to 0.41) | 0.39
PMID:40180416 · one of two readings recorded this
fasting blood glucose
decreases
curcumin significantly reduced fasting blood glucose (FBG) (WMD: 2.83; 95%CI: 4.61, −1.06; I2 = 51.3%)
PMID:40538540 · one of two readings recorded this
fasting blood glucose
decreases
curcumin reduced FBG (WMD: 3.618; 95%CI: 5.165, −2.071; I2 = 20.4%)
PMID:40538540 · one of two readings recorded this
fasting blood glucose
decreases, WMD -0.58, 95% CI -0.87 to -0.28
Overall, Mg supplementation was associated with a significant reduction in FBG levels compared to the control group in T2DM patients (WMD = –0.58, 95% CI: –0.87, –0.28; P < 0.01).
PMID:40641714 · one of two readings recorded this
fasting blood glucose
decreases, p = 0.00001
supplementation significantly reduced fasting blood glucose (FBG) (SMD: -0.53; 95% CI: -0.75 to -0.31; p < 0.00001)
PMID:40999397 · one of two readings recorded this
fasting blood glucose
decreases, p = 0.001
Fasting blood glucose levels increased in both groups, but the rise was significantly attenuated in the probiotic group (137.90 ± 21.98 to 139.00 ± 25.82 mg/dL, Δ = +1.143 mg/dL) compared to the placebo group (131.00 ± 20.59 to 143.50 ± 27.76 mg/dL, Δ = + 12.570 mg/dL), with a statistically significant between-group difference (p < 0.001)
PMID:41097174 · one of two readings recorded this
Fasting blood glucose
decreases, p = 0.047
The Post-hoc test showed significantly lower in CT + P (d: 4.21, p < 0.001), CT (d: 4.27, p < 0.001), S (d: 1.25, p = 0.047), and CT + S (d: 4.05, p < 0.001) compared with P group.
PMID:41249265 · one of two readings recorded this
Fasting blood glucose
p = 0.001
fasting blood glucose (F(5,83) = 45.39, p < 0.001, η2 = 0.777)
PMID:41249265 · one of two readings recorded this
Fasting blood glucose
decreases, p = 0.001
Also, the FBG were significantly lower in CT + S compared with S group (d: 2.81, p < 0.001).
PMID:41249265 · one of two readings recorded this
fasting blood glucose
decreases
The evidence showed a significant reduction in FBG, SMD = -0.22 (-0.39 to -0.05), HbA1c, MD = -1.00%, 95% CI (-1.92 to -0.07), and HOMA-IR, MD = -0.63, 95% CI (-1.20 to -0.06)
PMID:41599883 · one of two readings recorded this
fasting blood glucose
decreases
reductions in FBG (-7.33 mg/dL; 95% CI: -10.67 to -3.99)
PMID:41630501 · one of two readings recorded this
fasting blood glucose
no effect, SMD −0.149, 95% CI −0.257 to −0.041, p = 0.126
Not recorded as a finding: whole-population pooled estimate reported (node exists) but not selected as a claim
Resveratrol supplementation did not produce a statistically significant reduction in fasting blood glucose levels [SMD −0.149, 95% confidence interval (CI)=−0.257 to −0.041; I²=23.064%, p=0.126;.
PMID:41760304 · one of two readings recorded this
fasting blood glucose
no effect, p = 0.61, n = 389
A random‐effects meta‐analysis including 6 trials with a total of 389 participants (192 in the intervention group and 197 in the control group) found no significant difference in FBS levels after nanocurcumin supplementation [SMD: −0.44, 95% CI: (−2.16, 1.28), p = 0.61].
PMID:42171191 · one of two readings recorded this
fasting blood glucose
decreases, WMD -3.60 mg/dL, 95% CI -6.13 to -1.06
The pooled analysis revealed that Mg supplementation significantly reduced HOMA-IR (WMD: −0.48, 95% CI: −0.79, −0.18), serum HbA1c (WMD: −0.15%, 95% CI: −0.26, −0.03), and FBG (WMD: −3.60 mg/dL, 95% CI: −6.13, −1.06) in comparison with the placebo group.
PMID:42588058 · one of two readings recorded this
Sources cited
47 papers
- Subject
- fasting blood glucose
- Findings
- 47
- Papers
- 47
Effect of Sucralose Consumption on Gut Microbiota: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2026PMID:427948021 finding
Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.record2026PMID:418597721 finding
Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2026PMID:425943411 finding
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2026PMID:421711911 finding
The effects of coenzyme Q10 supplementation on glycemic control in diabetic and non-diabetic individuals: a systematic review and meta-analysis.record2026PMID:416305011 finding
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.record2025PMID:401804161 finding
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.record2025PMID:415152491 finding
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.record2025PMID:410965561 finding
Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2025PMID:408856031 finding
Effect of Magnesium Supplements on Improving Glucose Control, Blood Pressure and Lipid Profile in Patients With Type 2 Diabetes Mellitus: A systematic review and meta-analysis.record2025PMID:406417141 finding
Twelve-Week Curcumin Supplementation Improves Glucose Homeostasis and Gut Health in Prediabetic Older Adults: A Pilot, Double-Blind, Placebo-Controlled Trial.record2025PMID:406472691 finding
Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial.record2024PMID:396835701 finding
Effects of quercetin on polycystic ovary syndrome in animal models: a systematic review and meta-analysis.record2024PMID:386378761 finding
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.record2024PMID:388504401 finding
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.record2024PMID:387551421 finding
The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial.record2024PMID:382002531 finding
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.record2023PMID:370378911 finding
Effect of vitamin E intake on glycemic control and insulin resistance in diabetic patients: an updated systematic review and meta-analysis of randomized controlled trials.record2023PMID:368009651 finding
Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2023PMID:375987531 finding
Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.record2022PMID:360080641 finding
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.record2022PMID:356856021 finding
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.record2022PMID:352824551 finding
The effect of aspartame and sucralose intake on body weight measures and blood metabolites: role of their form (solid and/or liquid) of ingestion.record2022PMID:344205381 finding
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.record2022PMID:363130961 finding
The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.record2022PMID:353459911 finding
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.record2021PMID:345566701 finding
Effect of glutamine supplementation on cardiometabolic risk factors and inflammatory markers: a systematic review and meta-analysis.record2021PMID:338653131 finding
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.record2021PMID:349614181 finding
Folic Acid Supplementation Improves Glycemic Control for Diabetes Prevention and Management: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.record2021PMID:343718671 finding
Oral Magnesium Supplementation for Treating Glucose Metabolism Parameters in People with or at Risk of Diabetes: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.record2021PMID:348363291 finding
The role of lycopene for the amelioration of glycaemic status and peripheral antioxidant capacity among the Type II diabetes mellitus patients: a case-control study.record2021PMID:341803361 finding
Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice.record2020PMID:318331071 finding
L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2020PMID:329326441 finding
The effect of crocin supplementation on lipid concentrations and fasting blood glucose: A systematic review and meta-analysis and meta-regression of randomized controlled trials.record2020PMID:329517481 finding
The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials.record2020PMID:327556131 finding
Effect of Coenzyme Q10 on Insulin Resistance in Korean Patients with Prediabetes: A Pilot Single-Center, Randomized, Double-Blind, Placebo-Controlled Study.record2018PMID:301513731 finding
The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.record2018PMID:304177821 finding
The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2018PMID:303962071 finding
Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: a systematic review and meta-analysis of double-blind randomized controlled trials.record2016PMID:275304711 finding
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.record2014PMID:252618821 finding
Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials.record2014PMID:246958901 finding
Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.record2013PMID:229304031 finding
Higher magnesium intake is associated with lower fasting glucose and insulin, with no evidence of interaction with select genetic loci, in a meta-analysis of 15 CHARGE Consortium Studies.record2013PMID:233436701 finding
Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.record2011PMID:206341741 finding
Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus.record2010PMID:200226161 finding
Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus.record2008PMID:185555751 finding
Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials.record2006PMID:169783671 finding